Background:  A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF). Trial Registration No: Eudract-Nr. 2016-002299-28   NCT02929329 ( Link  Trial Status: enrolling  Enrolling Centers:  800 centers worldwide  About 8000 subjects will be randomized 1:1 receive OM twice per day   orally (BID PO) or matching placebo.  Core Study Team: 
© Christian Mueller, 2012 - 2019 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: July 2019
Home News Team Studies Publications Events Cooperations Contact Kristin Podkowik Thomas Stoll